Related Experiment Video
Updated: Jun 22, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review
Tejbir S Monga1, Mfonido Ekong2, Kayé Patrick3
1Internal Medicine, Spartan Health Sciences University, Vieux Fort, LCA.
Insights
Cardiac amyloidosis (CA) patients with atrial fibrillation (AF) require anticoagulation to prevent clots. Safe anticoagulant use is crucial for managing AF in CA, irrespective of risk scores, to minimize complications.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Cardiac amyloidosis (CA) is characterized by amyloid protein deposition in the heart.
- Progressive CA leads to heart dysfunction, arrhythmias like atrial fibrillation (AF), and heart failure.
- Atrial fibrillation in CA patients elevates the risk of intracardiac thrombi and thromboembolic events.
Purpose of the Study:
- To review atrial fibrillation in cardiac amyloidosis.
- To discuss anticoagulation therapy for managing thromboembolic risk in CA patients with AF.
- To emphasize safe anticoagulation practices and multidisciplinary care.
Main Methods:
- Literature review on atrial fibrillation in cardiac amyloidosis.
- Analysis of anticoagulation strategies for CA patients.
- Discussion of risk assessment and management of adverse events.
Main Results:
- Atrial fibrillation is a common complication in cardiac amyloidosis.
- Anticoagulation is essential for reducing thromboembolic risk in these patients.
- Safe administration of anticoagulants is paramount, regardless of CHA2DS2-VASc score.
Conclusions:
- Anticoagulant therapy should be administered to CA patients with AF, independent of their CHA2DS2-VASc score.
- A multidisciplinary approach is vital for managing CA, optimizing treatment, and minimizing risks such as bleeding and drug interactions.
Abstract:
Cardiac amyloidosis (CA) involves the abnormal deposition and accumulation of amyloid proteins in the heart muscle. A hallmark of disease progression is declining heart function, which can lead to structural irregularities, arrhythmias, and ultimately heart failure. Atrial fibrillation (AF) is the most common arrhythmia that presents in CA patients, and this arrhythmia is significant because it can moderately increase the risk of patients developing intracardiac thrombi, thereby putting them at risk for thromboembolic events. The management of this complication entails the use of anticoagulants like vitamin K antagonists and direct oral anticoagulants to reduce the risk of thrombus formation. This article seeks to review AF in CA and the use of anticoagulation therapy for the management and reduction of thromboembolic risk. The major conclusions of this review are centered around the need for safe administration of anticoagulant therapy to CA patients, regardless of their CHA2DS2-VASc risk score. This review highlights the importance of taking a multidisciplinary or collaborative approach to CA treatment to ensure that all aspects of this multifaceted disease can be properly managed while minimizing adverse events like bleeding risk and drug-drug interactions.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...